TG Therapeutics (FRA:NKB2) Cyclically Adjusted Revenue per Share: €0.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NKB2 TG Therapeutics Inc FRA:NKB2
82 GF Score
Price €47.40
GF Value €49.23
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Cyclically Adjusted Revenue per Share?

TG Therapeutics FRA:NKB2 -2.47% 82 Cyclically Adjusted Revenue per Share is €0.99 as of Mar. 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 82/100 and a GF Value™ of €49.23 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

TG Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €1.107. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TG Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 98.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 367.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of TG Therapeutics was 367.20% per year. The lowest was 268.40% per year. And the median was 317.80% per year.

As of today (2026-07-20), TG Therapeutics's current stock price is €47.40. TG Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.99. TG Therapeutics's Cyclically Adjusted PS Ratio of today is 47.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TG Therapeutics was 4896.00. The lowest was 27.41. And the median was 84.88.


TG Therapeutics  (FRA:NKB2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TG Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.40/0.99
=47.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TG Therapeutics was 4896.00. The lowest was 27.41. And the median was 84.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


TG Therapeutics Cyclically Adjusted Revenue per Share Related Terms


TG Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Cyclically Adjusted Revenue per Share Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.20 0.51 0.88

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.63 0.75 0.88 0.99

FRA:NKB2 vs HALO, KYMR, PCVX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:NKB2
82GF Score
TG Therapeutics Inc FRA:NKB2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.107/330.2130*330.2130
=1.107

Current CPI (Mar. 2026) = 330.2130.

TG Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.001 241.018 0.001
201609 0.001 241.428 0.001
201612 0.001 241.432 0.001
201703 0.001 243.801 0.001
201706 0.001 244.955 0.001
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 0.005 264.877 0.006
202106 0.010 271.696 0.012
202109 0.013 274.310 0.016
202112 0.015 278.802 0.018
202203 0.014 287.504 0.016
202206 0.004 296.311 0.004
202209 0.001 296.808 0.001
202212 0.001 296.797 0.001
202303 0.052 301.836 0.057
202306 0.105 305.109 0.114
202309 0.997 307.789 1.070
202312 0.258 306.746 0.278
202403 0.399 312.332 0.422
202406 0.428 314.175 0.450
202409 0.470 315.301 0.492
202412 0.645 315.605 0.675
202503 0.687 319.799 0.709
202506 0.753 322.561 0.771
202509 0.856 324.800 0.870
202512 1.032 324.054 1.052
202603 1.107 330.213 1.107

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.99 mean?
TG Therapeutics (FRA:NKB2) has a Cyclically Adjusted Revenue per Share of €0.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Cyclically Adjusted Revenue per Share too high?
TG Therapeutics' current Cyclically Adjusted Revenue per Share is €0.99. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Cyclically Adjusted Revenue per Share compare to HALO and KYMR?
TG Therapeutics' Cyclically Adjusted Revenue per Share of €0.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Cyclically Adjusted Revenue per Share is €0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €49.23, compared to a current price of €47.40 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.99. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Cyclically Adjusted Revenue per Share is €0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €47.40 is trading 3.7% below its estimated GF Value™ of €49.23. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for FRA:NKB2:

  • Cyclically Adjusted Revenue per Share: €0.99
  • GF Value™: €49.23 vs. price of €47.40 (3.7% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for FRA:NKB2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.40
Price
€49.23
GF Value